I know of nothing that prevented Pourhassan from purchasing stock during his long tenure as president. If he was privy to an unannounced material event, good or bad, he would be required to wait until the event was publicly disclosed before buying stock.
I have invested in many clinical stage biopharma companies, and in almost every case, other than Cytodyn, insiders, including the president, purchased company stock, and took stock in lieu of a large salary.
The fact that Pourhassan has taken a very large salary for many years, and purchased no stock in the company, is both disappointing and disconcerting.
LM
Market Data 
Markets 
AI
